Viewing nowCombinationGlucita Duo Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanol Bio Pharma Co., Ltd.

MFDS item code 202204575 · Approved 2022.12.21 · Insurance code 655605610
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used alongside dietary and exercise therapy to assist in blood sugar control for patients with type 2 diabetes. The combined action of sitagliptin and metformin helps effectively improve blood glucose levels. Therefore, this medication will be very helpful for those who need blood sugar management.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no history of prior antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may cause changes in blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).
This medication contains sitagliptin and metformin, so several precautions are necessary when using it. First, sitagliptin may cause rare but serious allergic reactions, with symptoms such as anaphylaxis or severe skin conditions. If such symptoms are suspected, discontinue use immediately and consult with a doctor. Second, there is a risk of acute pancreatitis with sitagliptin, so if abdominal pain, nausea, or vomiting occurs after taking the medication, inform medical personnel immediately. Third, metformin has a rare but potentially fatal side effect called lactic acidosis, so patients with renal dysfunction or liver impairment should not use it. Fourth, patients with moderate to severe renal impairment, acute infections, dehydration, severe heart disease, or women who are pregnant or breastfeeding should not take this medication. Fifth, irregular eating habits, excessive exercise, and drug interactions may increase the risk of hypoglycemia or lactic acidosis, so caution is needed. Sixth, this medication can cause hypoglycemia, so blood sugar changes should be closely monitored, especially when taken with insulin or sulfonylurea medications. Seventh, alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. Eighth, if undergoing surgery or in situations where renal function may change drastically, temporarily suspend the use of the medication and resume only once the condition stabilizes. Ninth, if any unusual symptoms such as skin rash, severe joint pain, or blistering skin disorders occur while taking this medication, consult a doctor immediately. Finally, it is important to regularly check for drug side effects with blood tests and renal function tests, as well as periodically assess vitamin B12 levels. During the use of this medication, adhere to these precautions, and consult medical personnel immediately if any suspicious symptoms occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air and moisture from entering. Additionally, avoid extremely hot or cold places, and it is advisable to store it at room temperature between 1°C and 30°C.
Dark red oval film-coated tablets
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanol Bio Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.